179 related articles for article (PubMed ID: 25267750)
41. How does sunitinib cause hypothyroidism?
Hershman JM; Liwanpo L
Thyroid; 2010 Mar; 20(3):243-4. PubMed ID: 20187779
[No Abstract] [Full Text] [Related]
42. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
Alasker A; Meskawi M; Sun M; Ismail S; Hanna N; Hansen J; Tian Z; Bianchi M; Perrotte P; Karakiewicz PI
Cancer Treat Rev; 2013 Jun; 39(4):388-401. PubMed ID: 23317510
[TBL] [Abstract][Full Text] [Related]
43. Reversible myocardial dysfunction in a young woman with metastatic renal cell carcinoma treated with sunitinib.
Szmit S; Nurzyński P; Szaluś N; Opolski G; Szczylik C
Acta Oncol; 2009; 48(6):921-5. PubMed ID: 19191048
[No Abstract] [Full Text] [Related]
44. Sunitinib-aggravated hypertension.
Rivera F; Benounna M; Sánchez de la Nieta MD
J Hypertens; 2009 Jul; 27(7):1502-3. PubMed ID: 19542988
[No Abstract] [Full Text] [Related]
45. Reversible posterior leukoencephalopathy syndrome induced by sunitinib.
Martín G; Bellido L; Cruz JJ
J Clin Oncol; 2007 Aug; 25(23):3559. PubMed ID: 17687168
[No Abstract] [Full Text] [Related]
46. Pulmonary artery thrombosis mimicking disease progression in metastatic renal cell carcinoma on Sunitinib.
Ahmad M; Prasad S; Krishna MV; Lavingia V
Indian J Cancer; 2016; 53(1):112-3. PubMed ID: 27146756
[No Abstract] [Full Text] [Related]
47. Leg ulcers associated with cutaneous vascular degeneration in a patient receiving pazopanib chemotherapy.
Hioki T; Takama H; Makita S; Chen KR; Watanabe D; Akiyama M
Eur J Dermatol; 2017 Oct; 27(5):546-547. PubMed ID: 29084643
[No Abstract] [Full Text] [Related]
48. Response to sunitinib in an adult patient with rhabdoid renal cell carcinoma.
De Vincenzo F; Zucali PA; Ceresoli GL; Colombo P; Simonelli M; Lorenzi E; Perrino M; Gianoncelli L; De Sanctis R; Graziotti P; Santoro A
J Clin Oncol; 2011 Jun; 29(18):e529-31. PubMed ID: 21483010
[No Abstract] [Full Text] [Related]
49. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
[TBL] [Abstract][Full Text] [Related]
50. [Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
Sikic D; Lüdecke G; Lieb V; Keck B
Urologe A; 2016 May; 55(5):648-52. PubMed ID: 27119958
[TBL] [Abstract][Full Text] [Related]
51. Eruptive melanocytic nevi in a patient undergoing treatment with sunitinib.
Jiménez-Gallo D; Albarrán-Planelles C; Linares-Barrios M; Martínez-Rodríguez A; Báez-Perea JM
JAMA Dermatol; 2013 May; 149(5):624-6. PubMed ID: 23677103
[No Abstract] [Full Text] [Related]
52. Pyoderma gangrenosum with the use of sunitinib.
Nadauld LD; Miller MB; Srinivas S
J Clin Oncol; 2011 Apr; 29(10):e266-7. PubMed ID: 21220606
[No Abstract] [Full Text] [Related]
53. Extensive necrotizing fasciitis associated with sunitinib therapy.
Piszczek J; Dalton B; Peters T; Ruether D; Urbanski S
Clin Genitourin Cancer; 2014 Apr; 12(2):e47-9. PubMed ID: 24445249
[No Abstract] [Full Text] [Related]
54. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
55. Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
Motzer RJ; Hutson TE; Cella D; Reeves J; Hawkins R; Guo J; Nathan P; Staehler M; de Souza P; Merchan JR; Boleti E; Fife K; Jin J; Jones R; Uemura H; De Giorgi U; Harmenberg U; Wang J; Sternberg CN; Deen K; McCann L; Hackshaw MD; Crescenzo R; Pandite LN; Choueiri TK
N Engl J Med; 2013 Aug; 369(8):722-31. PubMed ID: 23964934
[TBL] [Abstract][Full Text] [Related]
56. Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Eisen T; Sternberg CN; Robert C; Mulders P; Pyle L; Zbinden S; Izzedine H; Escudier B
J Natl Cancer Inst; 2012 Jan; 104(2):93-113. PubMed ID: 22235142
[TBL] [Abstract][Full Text] [Related]
57. Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.
Sorich MJ; Rowland A; Kichenadasse G; Woodman RJ; Mangoni AA
Br J Cancer; 2016 Jun; 114(12):1313-7. PubMed ID: 27228299
[TBL] [Abstract][Full Text] [Related]
58. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
Kondo T
Nihon Jinzo Gakkai Shi; 2012; 54(5):574-80. PubMed ID: 22991835
[No Abstract] [Full Text] [Related]
59. Everolimus and pazopanib: two new drugs for renal cell cancer.
Med Lett Drugs Ther; 2010 May; 52(1337):33-4. PubMed ID: 20431519
[No Abstract] [Full Text] [Related]
60. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
Park CY
Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]